[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-regurgitation-functional\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-regurgitation-functional":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,73,98,124,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100608089","early-phase-1-transcatheter-edge-to-edge-repair-in-moderate-and-exertional-induced-severe-mr-timer-100608089",false,"NCT07197021","TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER)","TEER In dynaMic sEvere Functional Mitral Regurgitation：A Multicenter, Randomized, Controlled Trial","Key Inclusion Criteria:\n\n1. Clinically significant functional mitral regurgitation (MR=2+ at rest and MR≥3+ under stress) as defined by European Association of Echocardiography, within 90 days prior to randomization and confirmed by the Echocardiography Core Laboratory Note: The TTE must be obtained after the subject has been stabilized on optimal therapy and has undergone revascularization and\u002For CRT, as appropriate\n2. Assessed by the investigator to be on optimal standard of care therapy for heart failure, according to current ESC\u002FHFA guidelines with no dose changes of heart failure drugs (with the exception of diuretics) during the last 2 weeks immediately prior to randomization.\n3. Symptomatic with documented New York Heart Association Class II, III or IV heart failure, despite optimal standard of care therapy, within 30 days preceding randomization\n4. Minimum of one documented hospitalization (acute care admission or emergency room visit) for heart failure within 12 months preceding randomization OR values of 300 pg\u002FmL for BNP or 1000 pg\u002FmL for NT-proBNP after optimal medical and\u002For device management within 90 days preceding randomization Note: BNP or NT-proBNP must be obtained after the subject has been stabilized on optimal therapy and has undergone revascularization and\u002For CRT, as appropriate\n5. Left ventricular ejection fraction (LVEF) of ≥ 20% Note: LVEF needs to be determined by one of the following methods: transthoracic echocardiography (TTE), contrast ventriculography, gated blood pool scan, cardiac magnetic resonance) within 90 days prior to randomization\n6. Patient is ambulatory and able to perform a 6MWT with the only limiting factor(s) being due to cardiovascular fitness\n\nKey Exclusion Criteria:\n\n1. Mitral regurgitation is primarily due to degenerative disease of the mitral valve apparatus (Degenerative MR) as determined by transesophageal echocardiography (TEE).\n2. Status 1 heart transplant or prior orthotropic heart transplantation.\n3. Introduction of a new heart failure drug class within the last 2 weeks prior to randomization.\n4. Evidence of acute coronary syndrome, transient ischemic attack or stroke within 90 days prior to randomization. Any percutaneous cardiovascular intervention, carotid surgery, cardiovascular surgery, or atrial fibrillation ablation within 90 days prior to randomization.\n5. Therapy with or without cardioverter-defibrillator (CRT or CRT-D), or Implantable Cardioverter Defibrillator (ICD)) within 90 day prior to randomization, or revision of any implanted rhythm management device within 90 days prior to randomization.\n6. Need for any cardiovascular surgery.\n7. Mitral valve surgery is considered the preferred therapeutic option for the subject\n8. Renal replacement therapy\n9. 6-Minute Walk Test (6MWT) distance \\> 475 meters\n10. Mitral Valve Area (MVA) by planimetry \\\u003C 4.0 cm2; if MVA by planimetry is not measurable, pressure half-time measurement is acceptable; MVA must be confirmed by the Echocardiography Core Laboratory","ALL","18 Years","90 Years",{"count":20,"type":21},540,"ESTIMATED","INTERVENTIONAL",[24],"NA","Functional mitral regurgitation is a highly dynamic disease. Some patients exhibit only moderate(2+) functional mitral regurgitation at rest, which deteriorates to moderate-to-severe or severe FMR(3+ or 4+) during stress-termed dynamic severe functional mitral regurgitation. Observational studies link this condition to worse outcomes, with mitral valve intervention offering potential benefits; however, high-quality evidence remains lacking.\n\nThe Transcatheter Edge-to-Edge Repair In DynaMic sEvere Functional Mitral Regurgitation trial aims to assess the safety and effectiveness of transcatheter edge-to-edge repair plus guideline-directed medical therapy versus guideline-directed medical therapy alone in symptomatic chronic heart failure patients with dynamic severe functional mitral regurgitation, defined as moderate regurgitation at rest deteriorating to severe during handgrip stress echocardiography.\n\nThis prospective, multi-center, randomized trial enrolls patients with dynamic severe functional mitral regurgitation confirmed by a core laboratory using handgrip stress echocardiography. Patients are randomized 1:1 to transcatheter edge-to-edge repair plus medical therapy or medical therapy alone. The primary endpoint is the composite of Cardiovascular death or heart failure hospitalization over the entire period.\n\nThis trial will provide critical evidence on transcatheter edge-to-edge repair in patients with dynamic severe functional mitral regurgitation, informing future treatment recommendations.",[27],"Mitral Regurgitation Functional",[29,30,31],"hand grip","TEER","dynamic","NOT_YET_RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":21},"2027-01-01",{"date":40,"type":21},"2034-12-31",{"name":42,"class":43},"Sun Yat-sen University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100647295","mitral-valve-edge-to-edge-repair-in-patients-with-exercise-induced-severe-mitral-regurgitation-100647295","NCT07709208","Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitation","Mitral Valve Edge-to-Edge Reconstruction in Patients With Exercise-Induced Severe Secondary Mitral Regurgitation and Heart Failure","MARCER","Inclusion Criteria:\n\n* Mild-to-moderate (1+\u002F2+) SMR at rest\n* Exacerbation of SMR to exercise-induced severe (3+\u002F4+) SMR defined by at least one of the following:\n\n  * 40 mm\\^2 EROA (30 mm\\^2 under low-flow condition) or\n  * regurgitant volume ≥60 mL (45 mL under low-flow condition) or\n  * regurgitant fraction ≥40% or\n  * increase by 13 mm\\^2 EROA from rest to exercise\n* Increase in natriuretic peptides defined as NT-proBNP:\n\n  * \\>250 pg\u002Fml (Sinus rhythm) or\n  * \\>600 pg\u002Fml (Atrial fibrillation) or\n  * HF hospitalization within 12 months prior to screening (defined as HF listed as the major reason for hospitalization)\n* NYHA class II-IV\n* Stable HF medication regimen (GDMT) for at least 30 days prior to index procedure\n* Patient deemed appropriate candidate for TEER by the local multidisciplinary heart team\n* Age ≥ 18 years old\n* Written Informed consent\n\nExclusion Criteria:\n\n* Hospitalization in past three months due to myocardial infarction, coronary artery bypass graft surgery, and\u002For unstable angina\n* LVEDD \\>70 mm\n* LVEF \\\u003C20%\n* Evidence of transient ischemic attack or stroke within three months prior to intervention\n* Percutaneous coronary intervention in the last 30 days\n* Subjects expected to require any cardiac surgery, including surgery for coronary artery disease or for pulmonic, aortic, or tricuspid valve disease within one year\n* Presence of primary renal dysfunction or significantly compromised renal function (eGFR \\\u003C30 ml\u002Fmin)\n* Severe right ventricular failure\n* Severe aortic stenosis (aortic valve area \\\u003C1.0 cm\\^2) or aortic regurgitation\n* Hemodynamic instability requiring inotropic support or mechanical heart circulatory support\n* Presence of a mechanical mitral heart valve, mitral bioprosthetic valve or mitral annuloplasty ring, indication for cardiac resynchronization therapy\n* Echocardiographic evidence of intracardiac mass, thrombus, or vegetation\n* Active endocarditis or infections requiring current antibiotic therapy\n* Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing HF other than SMR\n* Inability to exercise\n* Pregnancy or planning pregnancy within next12 months\n* Life expectancy \\\u003C12 months (judgement of investigator)\n* Anticipated need of left ventricular assist device within next 12 months\n* Participation in another interventional clinical trial (primary endpoint not yet reached) during this trial or within 30 days prior to enrolment into this trial\n* Previous participation in this trial",{"count":54,"type":21},246,[24],"The goal of this clinical trial is to learn whether mitral valve transcatheter edge-to-edge repair (TEER) in addition to guideline-directed medical therapy (GDMT) can improve clinical outcomes and symptoms in heart failure patients with non-severe secondary mitral regurgitation (SMR) at rest and exercise-induced severe SMR.\n\nThe main questions it aims to answer are:\n\n* Does mitral valve TEER in addition to GDMT lead to better overall clinical outcomes than GDMT alone in patients with heart failure and exercise-induced severe SMR?\n* Does mitral valve TEER reduce the risk of death, heart failure hospitalization, or worsening SMR during 12 months of follow-up compared with GDMT alone?\n* Does mitral valve TEER improve patients' quality of life compared with GDMT alone?\n\nParticipants will:\n\n* Undergo screening assessments to confirm eligibility for the study.\n* Be randomly assigned to receive either GDMT alone or GDMT plus mitral valve TEER.\n* Attend follow-up visits at approximately 3 time points during a 12-month follow-up period.\n* Undergo clinical evaluations that are routinely performed in patients with heart failure and SMR, including assessment of symptoms, functional status, and cardiac function.\n\nThe patients' echocardiographic data will undergo an additional centralized assessment by an independent Core Laboratory.",[58,27],"Heart Failure - NYHA II - IV",[60,61,62],"secondary mitral regurgitation","exercise-induced severe mitral regurgitation","dynamic mitral regurgitation","2026-08-10",{"date":65,"type":36},"2026-08-11",{"date":67,"type":21},"2026-08",{"date":69,"type":21},"2030-06",{"name":71,"class":43},"Jena University Hospital",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100651217","achieving-optimal-medical-therapy-through-percutaneous-treatment-of-secondary-mitral-regurgitation-to-improve-outcome-in-patients-with-hfref-100651217","NCT07758023","Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF","ACHILLES-HF","Inclusion Criteria:\n\n1. Heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction ≤40%)\n2. Clinically significant functional mitral regurgitation (moderate-to severe or severe MR) as defined by European Association of Echocardiography, within 90 days prior to randomization (i.e. EROA ≥0.2 cm² and\u002For regurgitant fraction \\>30%)\n3. Suboptimal GDMT therapy corresponding to a GDMT score \\\u003C7 points\n4. Risk factor for not intensification of guideline directed medical therapy (at least one of the following):\n\n   1. Office systolic blood pressure \\\u003C120 mmHG\n   2. Chronic renal failure with eGFR \\\u003C60 ml\u002Fmin\u002F1.73m\n   3. History of acute kidney injury (AKI) at least stage 2 within the last 12 months\n   4. Serum Potassium ≥ 4.8 mmol\u002FL\n5. Persisting symptoms equalling NYHA functional class II-IVa (ambulatory)\n6. Patient has had at least one HF hospitalization within 12 months and\u002For a NT-proBNP ≥1000 pg\u002Fml\n7. Interventional cardiologist believes secondary MR can be successfully treated by an interventional approach\n8. The subject has been informed of the nature of the study and agrees to the study's provisions, including the possibility of randomization to the Control group, and has provided written informed consent as approved by the respective clinical site's Ethics Committee\n\nExclusion Criteria:\n\n1. Terminal heart failure or hemodynamic instability\n2. Primary TR or MR, any other severe valvular heart disease\n3. Untreated clinically significant CAD (coronary artery disease) requiring revascularization\n4. LVEF \\\u003C35% and left bundle branch block with a QRS duration \\>150 ms\n5. Renal failure requiring dialysis\n6. Mitral valve orifice area \\\u003C4.0 cm² by site assessed TTE\n7. Life expectancy \\\u003C12 months due to non-cardiac conditions\n8. KCCQ score \\> 80 points\n9. Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)\n10. Active infections requiring current antibiotic therapy.\n11. Known hypersensitivity or contraindication to procedural device which cannot be adequately managed medically.\n12. Patient is pregnant, nursing, or planning to be pregnant\n13. Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the investigator.\n14. Currently participating in another investigational therapeutic or interventional clinical trial, or in any trial of an unapproved drug, device or procedure. Note: Subjects participating in observational studies or registries may be considered as eligible.\n15. Ineligibility to consent",{"count":81,"type":21},520,[24],"The purpose of the ACHILLES-HF trial (ACHIeving optimaL medicaL therapy through pErcutaneous treatment of Secondary mitral regurgitation to improve outcome in Patients with Heart Failure with reduced ejection fraction) is to test whether early transcatheter edge-to-edge repair (TEER) in patients with heart failure and reduced ejection fraction (HFrEF) and relevant secondary mitral regurgitation, that are at risk of not receiving full guideline recommended therapy (GDMT), results in faster and more complete GDMT up-titration and whether this translates into improved quality of life and clinical outcomes.",[27,85],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[87,88,89,90],"Mitral regurgitation","HFrEF","M-TEER","Guideline directed medical therapy","2026-08-05",{"date":65,"type":36},{"date":63,"type":21},{"date":95,"type":21},"2030-09-30",{"name":97,"class":43},"University Medical Center Mainz",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100631634","early-feasibility-study-efs-of-the-nyra-cardiac-leaflet-enhancer-carlen-system-100631634","NCT07503236","Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System","ENHANCE EFS: Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System","ENHANCE EFS","Key Inclusion Criteria:\n\n* Age \\> 21 years at time of enrollment\n* Patient has provided informed consent, is willing and capable of participating in all testing, and agrees to return for all required post-procedure follow-up visits\n* Moderate-to-severe or severe (MR ≥ 3+) functional (secondary) mitral valve regurgitation\n* Symptomatic with mitral regurgitation (NYHA Class II, III, or ambulatory IV) despite maximally-tolerated guideline-directed medical therapy (GDMT) as determined by the local multidisciplinary Heart Team\n* Patient is suitable for transcatheter mitral valve repair as determined by the local multidisciplinary Heart Team and confirmed by the Eligibility Committee\n\nKey Exclusion Criteria:\n\n* Estimated life expectancy of less than 12 months\n* Women who are pregnant, lactating, or planning to become pregnant during the clinical study. Women of child-bearing potential must have negative pregnancy test result within 2 weeks prior to the procedure\n* Left Ventricular Ejection Fraction (LVEF) \\\u003C 20%\n* Left ventricular end diastolic diameter (LVEDD) \\> 75 mm\n* Acute hemodynamic decompensation\n* Known hypersensitivity or contraindications to necessary and routine medications including contrast compounds or components used in the CARLEN System that cannot be successfully pre-medicated, including nitinol, an alloy of nickel and titanium\n* Contraindicated for transesophageal echo (TEE)\n* Presence of other anatomical characteristics and\u002For significant comorbidities that in the judgement of the Investigator or Eligibility Committee precludes the subject from participation\n* Aortic valve disease requiring intervention or intervention\n* Severe or greater tricuspid regurgitation\n* Severe right ventricular dysfunction\n* Severe pulmonary hypertension\n* Presence of significant congenital heart disease\n* Planned or scheduled cardiac surgery within next 12 months\n* Endocarditis within last 90 days\n* Evidence of intracardiac mass, vegetation, or inflammatory or infectious valve disease","21 Years",{"count":108,"type":21},30,[24],"Safety and performance evaluation of the CARLEN System in patients with functional mitral valve regurgitation.",[27],"RECRUITING","2026-07-27",{"date":115,"type":36},"2026-07-28",{"date":117,"type":36},"2026-07-02",{"date":119,"type":21},"2032-12",{"name":121,"class":122},"Nyra Medical, Inc.","INDUSTRY",3,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":44},"100611636","randomized-controlled-study-of-dragonfly-system-for-functional-mitral-regurgitation-100611636","NCT07243158","Randomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation","A Prospective, Multicenter, Randomized Controlled Clinical Study to Evaluate the Safety and Effectiveness of the DragonFly Transcatheter Mitral Valve Clip System in the Treatment of Moderate-to-Severe or Severe Functional Mitral Regurgitation (FMR)","Inclusion Criteria:\n\n1\\) Age ≥ 18 yrs. 2) Symptomatic functional mitral regurgitation (FMR) (≥3+) due to ischemic or non-ischemic cardiomyopathy\n\n* Transseptal catheterization and femoral vein access is determined to be feasible.\n* The subject or subject's legal representative has been informed of the nature of the trial, willing to accept the experimental tests, and has provided written informed consent.\n\nExclusion Criteria:\n\n1\\) Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2）Echocardiography revealed severe restriction of leaflet motion due to tethering.\n\n3\\) The presence of other severe heart valve disease requiring surgical intervention.\n\n* Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.\n* In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.",{"count":132,"type":21},148,[24],"To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after adequate treatment.",[27],"2025-11-17",{"date":138,"type":36},"2025-11-21",{"date":140,"type":21},"2025-12-30",{"date":142,"type":21},"2030-06-30",{"name":144,"class":122},"Hangzhou Valgen Medtech Co., Ltd",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100418798","safety-and-effectiveness-study-of-dragonfly-system-for-functional-mitral-regurgitation-100418798","NCT04733404","Safety and Effectiveness Study of Dragonfly System for Functional Mitral Regurgitation","A Prospective, Multicenter, Objective Performance Criteria Study to Evaluate the Safety and Effectiveness of Dragonfly Transcatheter Mitral Valve Repair System for the Treatment of Functional Mitral Regurgitation (FMR) Subjects.","Inclusion Criteria:\n\n1. Age ≥ 18 yrs.\n2. Symptomatic functional mitral regurgitation (FMR) (≥3+) due to ischemic or non-ischemic cardiomyopathy Note 1: Functional MR requires the presence of overall or localized LV wall motion abnormalities that are considered to be the primary cause of MR. Despite the eligibility, subjects may not enroll if leaflet prolapse or other evidence of degenerative MR is present.\n\n   Note 2: An Eligible transthoracic echocardiography must be obtained at least 30 days after the subject has been stabilized on optimal therapy with Guideline Directed Medical Therapy (GDMT), and after meeting two of the following conditions:\n   1. GDMT dose increase of no greater than 100% or decrease of no greater than 50%.\n   2. Coronary revascularization and\u002For implantation of a cardiac resynchronization therapy device (CRT or CRT-D) or reprogramming of the implanted CRT or CRT-D resulting in an increase in biventricular pacing (from \\\u003C92% to ≥92%).\n3. Subjects have been adequately treated according to applicable criteria, including treatment for coronary artery disease, left ventricular dysfunction, mitral regurgitation, and heart failure (e.g., with cardiac resynchronization therapy (CRT or CRT-D), coronary revascularization, and\u002For have received stable GDMT, as defined in (Appendix IV: Definition of GDMT), confirmed by the local heart team.\n4. NYHA functional class II to IVa.\n5. Left ventricular ejection fraction (LVEF) ≥ 20% and ≤50%.\n6. Left ventricular end-systolic dimension (LVESD) ≤ 70 mm.\n7. Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique and can be treated by the DragonflyTM device.\n8. Elevated BNP \\>150 pg\u002Fml or corrected NT-proBNP ≥600 pg\u002Fml or heart failure hospitalization within the past 12 months ('corrected' refers to a 4% reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg\u002Fm2 in BMI above a reference BMI of 20 kg\u002Fm2).\n9. Transseptal catheterization and femoral vein access is determined to be feasible.\n10. The subject or subject's legal representative has been informed of the nature of the trial, willing to accept the experimental tests, and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.\n2. The presence of other severe heart valve disease requiring surgical intervention.\n3. Prior mitral valve leaflet surgery or transcatheter mitral valve intervention.\n4. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis, sarcoidosis, etc.), or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.\n5. Moderate to severe right heart dysfunction or an estimated pulmonary artery systolic pressure (PASP) \\> 70 mmHg assessed by echocardiography.\n6. History of acute myocardial infarction in the prior 4 weeks or untreated clinically significant coronary artery disease requiring revascularization.\n7. Any percutaneous cardiac intervention within the 30 days, or any cardiac surgery within the 6 months prior to randomization, or any implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) or Implantable Cardioverter Defibrillator (ICD) within the last 30days prior to subject registration.\n8. In the judgment of the investigator, the subject's femoral vein is unable to accommodate a 25F catheter or has an ipsilateral deep venous thrombosis; or the anatomy is not accessible for transseptal puncture.\n9. Subjects in whom transesophageal echocardiography (TEE) or general anesthesia is contraindicated.\n10. End-stage heart failure (ACC\u002FAHA stage D), or prior orthotopic heart transplantation, or on the waiting list for heart transplantation.\n11. Active endocarditis, or active rheumatic heart disease, or leaflets degenerated from either endocarditis or rheumatic disease.\n12. Severe Chronic Obstructive Pulmonary Disease (COPD) (requiring continuous home oxygen therapy or long-term application of steroid hormone medication).\n13. Cerebrovascular accident within 30 days prior to randomization or symptomatic severe carotid stenosis (\\> 70% by ultrasound), or carotid artery stenting within 30 days.\n14. Evidence of acute peptic ulcer or gastrointestinal hemorrhage in the prior 3 months.\n15. Hemorrhagic or coagulopathic disorders, contraindications to antithrombotic medication.\n16. Modified Rankin Scale ≥4.\n17. The subjects suffer from diseases that may lead to difficulty in evaluating treatment (e.g., cancer, severe metabolic disease, psychosis, etc.).\n18. Pregnant or breastfeeding women, or women who plan to become pregnant within the next 12 months. Note: Women of childbearing age should take a pregnancy test with a negative result within 14 days prior to registration and use scientifically safe contraception\n19. Hemodynamic instability defined as systolic pressure \\\u003C 90 mmHg without afterload reduction, cardiogenic shock, or the need for inotropic support or an intra-aortic balloon pump.\n20. Active infections requiring antibiotic therapy (in the case of temporary illness, antibiotics must be discontinued for at least 14 days before the subject can be enrolled).\n21. Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.\n22. In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.",{"count":153,"type":21},120,[24],"To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.",[27],"2022-03-26",{"date":159,"type":36},"2022-03-29",{"date":161,"type":36},"2022-03-12",{"date":163,"type":21},"2027-09-30",{"name":144,"class":122}]